Expression levels of the apoptosis genes FAS, TNFR2, TRAIL, DR3 and DR4/5 in patients with newly diagnosed chronic lymphatic leukemia before and after treatment with fludarabine, cyclophosphamide and rituximab (FCR)
Background: We have previously shown that the FAS, TNFR2, TRAIL, DR3, DR4/5 gene expression in patients with newly diagnosed chronic lymphoblastic leukemia (CLL) correlates with clinical manifestations of the disease: they are minimal in patients with high activity of the proapoptotic genes and low...
Main Authors: | S. G. Zakharov, A. K. Golenkov, V. A. Misyurin, E. V. Kataeva, M. A. Baryshnikova, Yu. Yu. Chuksina, T. A. Mitina, E. V. Trifonova, L. L. Vysotskaya, Yu. B. Chernykh, E. F. Klinushkina, K. A. Belousov, Yu. P. Finashutina, A. V. Misyurin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
MONIKI
2018-12-01
|
Series: | Alʹmanah Kliničeskoj Mediciny |
Subjects: | |
Online Access: | https://www.almclinmed.ru/jour/article/view/933 |
Similar Items
-
Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01) -
Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01) -
VPP Participation in the FCR Cooperation Considering Opportunity Costs
by: Fernando J. Ribeiro, et al.
Published: (2024-04-01) -
Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population
by: Stefano Molica, et al.
Published: (2024-03-01) -
Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)